Published in Immunity on October 01, 2000
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A (2004) 2.27
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med (2001) 1.57
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J Exp Med (2008) 1.38
CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J Exp Med (2001) 1.38
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature (2016) 1.30
Cancer vaccines: progress reveals new complexities. J Clin Invest (2002) 1.29
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain. J Virol (2001) 1.24
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest (2002) 1.05
Immunization against endogenous retroviral tumor-associated antigens. Cancer Res (2001) 1.05
Fluorine substitutions in an antigenic peptide selectively modulate T-cell receptor binding in a minimally perturbing manner. Biochem J (2009) 1.00
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol (2009) 0.99
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A (2010) 0.96
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest (2001) 0.94
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A (2002) 0.92
Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect Immun (2009) 0.91
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy. J Immunother (2015) 0.89
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother (2012) 0.89
Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One (2009) 0.88
A human dendritic cell-based method to identify CD4+ T-cell epitopes in potential protein allergens. Environ Health Perspect (2003) 0.87
Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. J Immunol (2014) 0.87
Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking. PLoS Pathog (2009) 0.85
Dissociation of peripheral T cell responses from thymocyte negative selection by weak agonists supports a spare receptor model of T cell activation. Proc Natl Acad Sci U S A (2002) 0.85
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res (2012) 0.84
Immune rejection of mouse tumors expressing mutated self. Cancer Res (2009) 0.84
Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. J Immunother Cancer (2014) 0.83
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PLoS One (2013) 0.83
Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4. Clin Dev Immunol (2011) 0.83
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J Immunol (2009) 0.82
Development and use of multimeric major histocompatibility complex molecules. Clin Diagn Lab Immunol (2002) 0.81
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display. Protein Eng Des Sel (2011) 0.80
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immun Ageing (2011) 0.80
Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol (2011) 0.78
A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods (2011) 0.78
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins. Curr Protoc Immunol (2009) 0.77
An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. PLoS One (2014) 0.77
Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides. Front Immunol (2015) 0.77
Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/K(b) Transgenic Mice. Front Immunol (2016) 0.77
Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin. J Zhejiang Univ Sci B (2016) 0.76
Helper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L. Oncoimmunology (2013) 0.76
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse. Clin Dev Immunol (2013) 0.76
Progress in cancer vaccines by enhanced self-presentation. Proc Natl Acad Sci U S A (2001) 0.75
Viral Escape Mutant Epitope Maintains TCR Affinity for Antigen yet Curtails CD8 T Cell Responses. PLoS One (2016) 0.75
Flanking residues are central to DO11.10 T cell hybridoma stimulation by ovalbumin 323-339. PLoS One (2012) 0.75
MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth. Immun Inflamm Dis (2014) 0.75
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet (1977) 5.65
The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 4.35
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 4.19
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature (1987) 3.96
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Structure and expression of a mouse major histocompatibility antigen gene, H-2Ld. Proc Natl Acad Sci U S A (1982) 3.73
Molecular and cellular events of T cell development. Adv Immunol (1989) 3.50
Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature (1982) 3.34
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 3.32
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Somatic cell hybridization of mouse myeloma cells. Cell (1976) 3.17
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature (1988) 2.84
T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science (1994) 2.81
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A (1987) 2.57
Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity (1999) 2.55
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer. J Immunol (1983) 2.45
Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity (2001) 2.44
Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science (1986) 2.40
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells. Proc Natl Acad Sci U S A (1981) 2.22
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
Effects of cyclosporine A on T cell development and clonal deletion. Science (1988) 2.08
T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev (1987) 2.07
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Differential expression of two distinct T-cell receptors during thymocyte development. Nature (1987) 1.95
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95
"Exon-shuffling" maps control of antibody- and T-cell-recognition sites to the NH2-terminal domain of the class II major histocompatibility polypeptide A beta. Proc Natl Acad Sci U S A (1985) 1.93
The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol (1991) 1.90
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 1.89
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 1.86
Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med (1994) 1.74
Allospecific and virus-specific cytolytic T lymphocytes are restricted to the N or C1 domain of H-2 antigens expressed on L cells after DNA-mediated gene transfer. Proc Natl Acad Sci U S A (1983) 1.74
Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature (1999) 1.69
Properties of the specific binding of 125I-nerve growth factor to responsive peripheral neurons. J Biol Chem (1974) 1.68
Localization of SV40 genes within supercoiled loop domains. Nucleic Acids Res (1980) 1.68
Hybrid H-2 histocompatibility gene products assign domains recognized by alloreactive T cells. Proc Natl Acad Sci U S A (1983) 1.67
Membrane Ia expression and antigen-presenting accessory cell function of L cells transfected with class II major histocompatibility complex genes. J Exp Med (1984) 1.65
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med (1987) 1.63
Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J Immunol (1995) 1.58
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Tumour antigens. A new look for the 1990s. Nature (1994) 1.56
H-2-like genes in the Tla region of mouse chromosome 17. Nature (1982) 1.54
T-cell recognition of a chimaeric class II/class I MHC molecule and the role of L3T4. Nature (1985) 1.53
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med (1992) 1.46
Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res (1995) 1.45
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med (1992) 1.43
Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J Immunol (1995) 1.42
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J Mol Biol (1996) 1.41
A T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. Eur J Immunol (2001) 1.41
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer (1998) 1.38
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A (1993) 1.36
In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36
Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J Exp Med (1989) 1.35
Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer (2005) 1.29
Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol (1977) 1.28
H-2 hemizygous mutants from a heterozygous cell line: role of mitotic recombination. EMBO J (1983) 1.28
Minimal requirements for peptide mediated activation of CD8+ CTL. Mol Immunol (1994) 1.28
Major histocompatibility complex conformational epitopes are peptide specific. J Exp Med (1992) 1.28
Host MHC class I molecules modulate in vivo expression of a NK cell receptor. J Immunol (1994) 1.25
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature (1991) 1.22
Functional expression of a transfected murine class II MHC gene. Nature (1984) 1.22
Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry (1995) 1.20
Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur J Immunol (1999) 1.20
A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity (1995) 1.17
Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int Immunol (2001) 1.17
Interaction of nerve growth factor with surface membranes: biological competence of insolubilized nerve growth factor. Proc Natl Acad Sci U S A (1973) 1.17